Ind-Swift Laboratories Limited announced a private placement that it will issue up to 26,000,000 convertible warrants Convertible into equivalent number of Equity Shares of INR 10 each within a maximum period of 18 months from the date of allotment of such Warrants on June 27, 2024. The transaction will include participation from new investors such as Essix Biosciences Limited; Hcp Investments; Zeal Global Opportunities Fund and Saral Incorporated VCC Sub Fund 1. The issue price maybe determined by the Board/ Committee of Directors in accordance with provisions of Chapter V of SEBI ICDR Regulations, as amended and applicable provisions of the Companies Act, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.3 INR | +4.86% | +2.62% | +28.76% |
1st Jan change | Capi. | |
---|---|---|
+28.76% | 89.97M | |
+24.53% | 44.76B | |
+30.99% | 23.16B | |
+24.13% | 16.02B | |
+21.15% | 14.32B | |
+68.67% | 13.7B | |
-0.05% | 6.79B | |
-13.29% | 6.47B | |
-8.87% | 5.73B | |
+13.53% | 5.65B |
- Stock Market
- Equities
- INDSWFTLAB Stock
- News Ind-Swift Laboratories Limited
- Ind-Swift Laboratories Limited announced that it expects to receive funding from Essix Biosciences Limited, Hcp Investments, Zeal Global Opportunities Fund